NanoViricides Inc. (NNVC)

[changes_iv]

Your "compadres", those that cackle/post ad nauseum with "missing links", were proclaiming the deletion of NNVC from Russell 2000. The posters now proclaim a sell-off will begin and now you (better late than never) say, "...isn't a high dollar value source of fund participation" as if saying, it doesn't matter...?!?

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111465123

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113445166

In this report we present our latest predictions for the upcoming Russell Annual Reconstitution. Our analysis uses market data as of the close Friday, which is the official Russell ranking date. In addition to constituent changes, we have included our anticipated Growth/Value style and float factor changes that will be implemented at the Reconstitution.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=102940919

[The FACTS are that there is no pharma company out there that has a drug for the FLU, one that is as safe and effective as FluCide(TM). You can find government "juiced up" companies with goals for a broad spectrum drug but none with preclinical studies results like FluCide(TM):]

NanoViricides, Inc. - FluCide(TM) - About FluCide(TM) Data presented at the 3rd Annual Influenza Conference held by GTC Bio on Friday, July 11

The Company believes that its FluCide™ drug candidate will be effective against most if not all influenza viruses, including the H7N9 bird flu, H3N2 or H1N1 epidemic viruses, H5N1 bird flu, seasonal influenzas, as well as novel influenza viruses. This is because FluCide is based on the Company’s biomimetic technology, mimicking the natural sialic acid receptors for the influenza virus on the surface of a nanoviricide® polymeric micelle. It is important to note that all influenza viruses bind to the sialic acid receptors, even if they rapidly mutate. The FluCide drug candidates have already shown strong effectiveness against H1N1 and H3N2 influenza viruses in highly lethal animal models. The injectable FluCide drug candidate has shown 1,000X greater viral load reduction as compared to oseltamivir (Tamiflu®), the current standard of care, in a highly lethal influenza infection animal model. The Company believes that these animal model results should translate readily into humans.

NanoViricides has also developed an oral drug candidate against influenza. This oral version was found to be dramatically more effective than oseltamivir (TamiFlu®) in animals given a highly lethal level of influenza virus infection. This oral FluCide may be the very first nanomedicine that is effective when taken by mouth.

Read more:
http://finance.yahoo.com/news/nanoviricides-president-dr-diwan-presented-120000451.html

http://www.prnewswire.com/news-releases/nanoviricides-provides-an-update-on-its-progress-over-the-last-quarter-300061129.html

We are now progressing to a 1kg scale-up of FluCide, and enabling in-process control instrumentation. We need to make approximately 2.5Kg of our FluCide drug candidate for further Tox Package studies because of the excellent safety demonstrated by this drug candidate in safety and toxicology studies in both mouse and rat animal models. CMC stands for "Chemistry, Manufacture, and Controls," and relates to being able to make the drug substance and the drug product in a reproducible fashion, batch after batch. CMC programs for nanomedicines are relatively complex compared to those of small molecules. We have focused on developing scalable, reproducible processes from the very onset, which has helped us minimize the process development time.
http://www.nanoviricides.com/press%20releases/2015/NanoViricides%20Files%20Quarterly%20Report%20for%20Period%20Ending%202015-03-31.html

[Seems to me they have completed the 1kg scale-up recipe and about 1kg is all we will need for clinical trials.]

June 1, 2015, 9:47 PM

FluCide

Phase I and II of tox successfully completed

Making material for last Phase in large animals

MersCide

Waiting for Public Health England to request the drug (sitting on the shelf) for testing. They got distracted by the Ebola outbreak

EbolaCide

Making more drug for continuation of the testing by USAMRIID

Had FluCide not turned out to be so incredibly safe, we would have been done with tox by now. Incredibly safe is not a bad thing at all!

Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
[e-mail]
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange

======================================

Midsummer Nights' Science: Miniature science - How microfluidics is powering biology
...
Miniaturized lab-on-a-chip methods are being deployed as labor-saving devices in biological research, through the advent of a suite of microfluidics technologies. Microfluidics enables large-scale studies that provide the means to better understand, prevent, and treat human disease. In his 2012 Midsummer Nights' Science lecture, Paul Blainey discusses the promise of using microfluidics to transform our industrial infrastructure to operate more efficiently, while protecting the natural environment.
...

Targeted polymeric therapeutic nanoparticles: design, development and clinical translation (2013)
...
7. Novel trends in the development of targeted polymeric nanoparticles
7.1 Multi-targeting
...
Multi targeting systems (MTS) generally describe NP surfaces decorated with two or more targeting ligands that recognize different receptors on the same or different cells. This type of targeting has gained a substantial amount of interest as a way to increase NP uptake by cancer cells using a “two-punch” (or “three-punch”) approach...

7.2 Screening NP libraries
...
Small-molecule drug discovery is generally conducted by screening libraries of molecules to find drugs with optimal pharmacokinetics, biodistribution, tolerance, disposition, and elimination profiles. In recent years researchers have also taken this approach for the development of targeted NPs. However, targeted NP screening increases complexity by several orders of magnitude since there are several ‘inputs’ that could be screened for, such as chemical diversity from the precursors, or biophysicochemical diversity from the NPs. Careful design of combinatorial methods for measuring and understanding these diversities is one solution...

9. Conclusions and outlook
...
We have confidence that with a well characterized system including: safe, effective, and specific targeting ligands, biocompatible, biodegradable and bioeliminable materials, and appropriate choice of therapeutics and disease models, targeted polymeric NPs could yield more effective treatments for a myriad of important human diseases. The exciting developments that are producing more “sensitive” NPs capable of triggered release of drugs at active sites under environmental cues further strengthen the therapeutic NP arsenal. Although targeted NPs have been slow to enter the clinic their potential as an entirely new class of therapeutics, remains tremendous.

A considerable amount of research and development is necessary from the proof-of-principle stage of developing novel targeted nanomedicines to their bench-to-bedside translation, and in particular, the multifunctionality and complexity of some targeted polymeric NPs should be investigated on a case-by-case basis. The processes for the engineering of targeted NPs must be carefully developed and controlled in order to facilitate reproducible and scalable NP production...

Read more: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684255/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684255/